Tenax Other Stockholder Equity from 2010 to 2025
| TENX Stock | USD 6.18 0.05 0.82% |
Other Stockholder Equity | First Reported 1996-09-30 | Previous Quarter 313.5 M | Current Value 405.8 M | Quarterly Volatility 113.5 M |
Check Tenax Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tenax Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.3 K, Other Operating Expenses of 8.4 M or Research Development of 13.3 M, as well as many indicators such as Price To Sales Ratio of 141.3 K, Dividend Yield of 3.31 or PTB Ratio of 10.79. Tenax financial statements analysis is a perfect complement when working with Tenax Therapeutics Valuation or Volatility modules.
Tenax | Other Stockholder Equity |
Latest Tenax Therapeutics' Other Stockholder Equity Growth Pattern
Below is the plot of the Other Stockholder Equity of Tenax Therapeutics over the last few years. It is Tenax Therapeutics' Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tenax Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Other Stockholder Equity | 10 Years Trend |
|
Other Stockholder Equity |
| Timeline |
Tenax Other Stockholder Equity Regression Statistics
| Arithmetic Mean | 234,290,555 | |
| Geometric Mean | 183,852,013 | |
| Coefficient Of Variation | 45.28 | |
| Mean Deviation | 71,123,431 | |
| Median | 239,572,094 | |
| Standard Deviation | 106,097,019 | |
| Sample Variance | 11256.6T | |
| Range | 421.7M | |
| R-Value | 0.92 | |
| Mean Square Error | 1835.8T | |
| R-Squared | 0.85 | |
| Slope | 20,518,776 | |
| Total Sum of Squares | 168848.7T |
Tenax Other Stockholder Equity History
About Tenax Therapeutics Financial Statements
Tenax Therapeutics investors use historical fundamental indicators, such as Tenax Therapeutics' Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tenax Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Stockholder Equity | 406.8 M | 427.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.